Search

Your search keyword '"SOMWAR, ROMEL"' showing total 242 results
Start Over Author "SOMWAR, ROMEL" Publication Year Range Last 3 years
242 results on '"SOMWAR, ROMEL"'

2. Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

Author

Miyazaki, Isao, Odintsov, Igor, Ishida, Keiji, Lui, Allan J. W., Kato, Masanori, Suzuki, Tatsuya, Zhang, Tom, Wakayama, Kentaro, Kurth, Renate I., Cheng, Ryan, Fujita, Hidenori, Delasos, Lukas, Vojnic, Morana, Khodos, Inna, Yamada, Yukari, Ishizawa, Kota, Mattar, Marissa S., Funabashi, Kaoru, Chang, Qing, Ohkubo, Shuichi, Yano, Wakako, Terada, Ryuichiro, Giuliano, Claudio, Lu, Yue Christine, Bonifacio, Annalisa, Kunte, Siddharth, Davare, Monika A., Cheng, Emily H., de Stanchina, Elisa, Lovati, Emanuela, Iwasawa, Yoshikazu, Ladanyi, Marc, and Somwar, Romel

Published
2023
Full Text
View/download PDF

5. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification

Author

Elkrief, Arielle, Odintsov, Igor, Markov, Vladimir, Caeser, Rebecca, Sobczuk, Pawel, Tischfield, Sam E., Bhanot, Umesh, Vanderbilt, Chad M., Cheng, Emily H., Drilon, Alexander, Riely, Gregory J., Lockwood, William W., de Stanchina, Elisa, Tirunagaru, Vijaya G., Doebele, Robert C., Quintanal-Villalonga, Álvaro, Rudin, Charles M., Somwar, Romel, and Ladanyi, Marc

Published
2023
Full Text
View/download PDF

6. Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

Author

Miyazaki, Isao, Odintsov, Igor, Ishida, Keiji, Lui, Allan J. W., Kato, Masanori, Suzuki, Tatsuya, Zhang, Tom, Wakayama, Kentaro, Kurth, Renate I., Cheng, Ryan, Fujita, Hidenori, Delasos, Lukas, Vojnic, Morana, Khodos, Inna, Yamada, Yukari, Ishizawa, Kota, Mattar, Marissa S., Funabashi, Kaoru, Chang, Qing, Ohkubo, Shuichi, Yano, Wakako, Terada, Ryuichiro, Giuliano, Claudio, Lu, Yue Christine, Bonifacio, Annalisa, Kunte, Siddharth, Davare, Monika A., Cheng, Emily H., de Stanchina, Elisa, Lovati, Emanuela, Iwasawa, Yoshikazu, Ladanyi, Marc, and Somwar, Romel

Published
2023
Full Text
View/download PDF

8. Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells

Author

Johnson, Fraser D., Ferrarone, John, Liu, Alvin, Brandstädter, Christina, Munuganti, Ravi, Farnsworth, Dylan A., Lu, Daniel, Luu, Jennifer, Sihota, Tianna, Jansen, Sophie, Nagelberg, Amy, Shi, Rocky, Forcina, Giovanni C., Zhang, Xu, Cheng, Grace S.W., Spencer Miko, Sandra E., de Rappard-Yuswack, Georgia, Sorensen, Poul H., Dixon, Scott J., Guha, Udayan, Becker, Katja, Djaballah, Hakim, Somwar, Romel, Varmus, Harold, Morin, Gregg B., and Lockwood, William W.

Published
2022
Full Text
View/download PDF

11. Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy

Author

Kazansky, Yaniv, primary, Cameron, Daniel, additional, Mueller, Helen S., additional, Demarest, Phillip, additional, Zaffaroni, Nadia, additional, Arrighetti, Noemi, additional, Zuco, Valentina, additional, Kuwahara, Yasumichi, additional, Somwar, Romel, additional, Ladanyi, Marc, additional, Qu, Rui, additional, de Stanchina, Elisa, additional, Dela Cruz, Filemon S., additional, Kung, Andrew L., additional, Gounder, Mrinal M., additional, and Kentsis, Alex, additional

Published
2024
Full Text
View/download PDF

12. Prevalence and Therapeutic Targeting of High Level ERBB2 Amplification in Non-Small Cell Lung Cancer

Author

Odintsov, Igor, primary, Makarem, Maisam, additional, Nishino, Mizuki, additional, Bachert, Sara Emily, additional, Zhang, Tom, additional, LoPiccolo, Jaclyn, additional, Paweletz, Cloud P., additional, Gokhale, Prafulla C., additional, Ivanova, Elena, additional, Saldanha, Aisha, additional, Rudin, Charles M., additional, Lockwood, William W., additional, Ladanyi, Marc, additional, Somwar, Romel, additional, Jänne, Pasi A., additional, and Sholl, Lynette M., additional

Published
2023
Full Text
View/download PDF

14. HER4 and EGFR activate cell signaling in NRG1 fusion-driven cancers: implications for HER2/HER3-specific vs. pan-HER targeting strategies

Author

Udagawa, Hibiki, primary, Nilsson, Monique B., additional, Robichaux, Jacqulyne P., additional, He, Junqin, additional, Poteete, Alissa, additional, Jiang, Hong, additional, Heeke, Simon, additional, Elamin, Yasir Y., additional, Shibata, Yuji, additional, Matsumoto, Shingo, additional, Yoh, Kiyotaka, additional, Okazaki, Shogo, additional, Masuko, Takashi, additional, Odintsov, Ignor, additional, Somwar, Romel, additional, Ladanyi, Marc, additional, Goto, Koichi, additional, and Heymach, John V., additional

Published
2023
Full Text
View/download PDF

16. Abstract 6127: MDM2 inhibition in combination with MEK inhibition in pre-clinical models of lung adenocarcinomas with MDM2 amplification

Author

Elkrief, Arielle, primary, Markov, Vladimir, additional, Quintanal-Villalonga, Álvaro, additional, Caeser, Rebecca, additional, Sobczuk, Pawel, additional, Cheng, Emily, additional, Drilon, Alexander, additional, Riely, Gregory J., additional, Lockwood, William W., additional, de Stanchina, Elisa, additional, Rudin, Charles M., additional, Odintsov, Igor, additional, and Somwar, Romel, additional

Published
2023
Full Text
View/download PDF

17. Supplementary Table from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

Author

Schram, Alison M., primary, Odintsov, Igor, primary, Espinosa-Cotton, Madelyn, primary, Khodos, Inna, primary, Sisso, Whitney J., primary, Mattar, Marissa S., primary, Lui, Allan J.W., primary, Vojnic, Morana, primary, Shameem, Sara H., primary, Chauhan, Thrusha, primary, Torrisi, Jean, primary, Ford, Jim, primary, O'Connor, Marie N., primary, Geuijen, Cecile A.W., primary, Schackmann, Ron C.J., primary, Lammerts van Bueren, Jeroen J., primary, Wasserman, Ernesto, primary, de Stanchina, Elisa, primary, O'Reilly, Eileen M., primary, Ladanyi, Marc, primary, Drilon, Alexander, primary, and Somwar, Romel, primary

Published
2023
Full Text
View/download PDF

18. Abstract 4007: Efficacy of vepafestinib in preclinical models of RET fusion-driven sarcoma models

Author

Odintsov, Igor, primary, Cheng, Ryan C., additional, Lui, Allan J., additional, Zhang, Tom, additional, Lu, Yue C., additional, Kurth, Renate I., additional, Vojnic, Morana, additional, Khodos, Inna, additional, Chang, Qing, additional, Chen, Kevin, additional, Giuliano, Claudio, additional, Bonifacio, Annalisa, additional, Miyazaki, Isao, additional, Stanchina, Elisa de, additional, Lovati, Emanuela, additional, Ladanyi, Marc, additional, and Somwar, Romel, additional

Published
2023
Full Text
View/download PDF

19. Supplementary Figure from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

Author

Schram, Alison M., primary, Odintsov, Igor, primary, Espinosa-Cotton, Madelyn, primary, Khodos, Inna, primary, Sisso, Whitney J., primary, Mattar, Marissa S., primary, Lui, Allan J.W., primary, Vojnic, Morana, primary, Shameem, Sara H., primary, Chauhan, Thrusha, primary, Torrisi, Jean, primary, Ford, Jim, primary, O'Connor, Marie N., primary, Geuijen, Cecile A.W., primary, Schackmann, Ron C.J., primary, Lammerts van Bueren, Jeroen J., primary, Wasserman, Ernesto, primary, de Stanchina, Elisa, primary, O'Reilly, Eileen M., primary, Ladanyi, Marc, primary, Drilon, Alexander, primary, and Somwar, Romel, primary

Published
2023
Full Text
View/download PDF

20. Data from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

Author

Schram, Alison M., primary, Odintsov, Igor, primary, Espinosa-Cotton, Madelyn, primary, Khodos, Inna, primary, Sisso, Whitney J., primary, Mattar, Marissa S., primary, Lui, Allan J.W., primary, Vojnic, Morana, primary, Shameem, Sara H., primary, Chauhan, Thrusha, primary, Torrisi, Jean, primary, Ford, Jim, primary, O'Connor, Marie N., primary, Geuijen, Cecile A.W., primary, Schackmann, Ron C.J., primary, Lammerts van Bueren, Jeroen J., primary, Wasserman, Ernesto, primary, de Stanchina, Elisa, primary, O'Reilly, Eileen M., primary, Ladanyi, Marc, primary, Drilon, Alexander, primary, and Somwar, Romel, primary

Published
2023
Full Text
View/download PDF

26. Data from Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers

Author

Drilon, Alexander, primary, Somwar, Romel, primary, Mangatt, Biju P., primary, Edgren, Henrik, primary, Desmeules, Patrice, primary, Ruusulehto, Anja, primary, Smith, Roger S., primary, Delasos, Lukas, primary, Vojnic, Morana, primary, Plodkowski, Andrew J., primary, Sabari, Joshua, primary, Ng, Kenneth, primary, Montecalvo, Joseph, primary, Chang, Jason, primary, Tai, Huichun, primary, Lockwood, William W., primary, Martinez, Victor, primary, Riely, Gregory J., primary, Rudin, Charles M., primary, Kris, Mark G., primary, Arcila, Maria E., primary, Matheny, Christopher, primary, Benayed, Ryma, primary, Rekhtman, Natasha, primary, Ladanyi, Marc, primary, and Ganji, Gopinath, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figures from Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers

Author

Drilon, Alexander, primary, Somwar, Romel, primary, Mangatt, Biju P., primary, Edgren, Henrik, primary, Desmeules, Patrice, primary, Ruusulehto, Anja, primary, Smith, Roger S., primary, Delasos, Lukas, primary, Vojnic, Morana, primary, Plodkowski, Andrew J., primary, Sabari, Joshua, primary, Ng, Kenneth, primary, Montecalvo, Joseph, primary, Chang, Jason, primary, Tai, Huichun, primary, Lockwood, William W., primary, Martinez, Victor, primary, Riely, Gregory J., primary, Rudin, Charles M., primary, Kris, Mark G., primary, Arcila, Maria E., primary, Matheny, Christopher, primary, Benayed, Ryma, primary, Rekhtman, Natasha, primary, Ladanyi, Marc, primary, and Ganji, Gopinath, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Table from Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers

Author

Drilon, Alexander, primary, Somwar, Romel, primary, Mangatt, Biju P., primary, Edgren, Henrik, primary, Desmeules, Patrice, primary, Ruusulehto, Anja, primary, Smith, Roger S., primary, Delasos, Lukas, primary, Vojnic, Morana, primary, Plodkowski, Andrew J., primary, Sabari, Joshua, primary, Ng, Kenneth, primary, Montecalvo, Joseph, primary, Chang, Jason, primary, Tai, Huichun, primary, Lockwood, William W., primary, Martinez, Victor, primary, Riely, Gregory J., primary, Rudin, Charles M., primary, Kris, Mark G., primary, Arcila, Maria E., primary, Matheny, Christopher, primary, Benayed, Ryma, primary, Rekhtman, Natasha, primary, Ladanyi, Marc, primary, and Ganji, Gopinath, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Methods from Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers

Author

Drilon, Alexander, primary, Somwar, Romel, primary, Mangatt, Biju P., primary, Edgren, Henrik, primary, Desmeules, Patrice, primary, Ruusulehto, Anja, primary, Smith, Roger S., primary, Delasos, Lukas, primary, Vojnic, Morana, primary, Plodkowski, Andrew J., primary, Sabari, Joshua, primary, Ng, Kenneth, primary, Montecalvo, Joseph, primary, Chang, Jason, primary, Tai, Huichun, primary, Lockwood, William W., primary, Martinez, Victor, primary, Riely, Gregory J., primary, Rudin, Charles M., primary, Kris, Mark G., primary, Arcila, Maria E., primary, Matheny, Christopher, primary, Benayed, Ryma, primary, Rekhtman, Natasha, primary, Ladanyi, Marc, primary, and Ganji, Gopinath, primary

Published
2023
Full Text
View/download PDF

41. Figure S1 from Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor

Author

Ogura, Koichi, primary, Somwar, Romel, primary, Hmeljak, Julija, primary, Magnan, Heather, primary, Benayed, Ryma, primary, Momeni Boroujeni, Amir, primary, Bowman, Anita S., primary, Mattar, Marissa S., primary, Khodos, Inna, primary, de Stanchina, Elisa, primary, Jungbluth, Achim, primary, Asher, Marina, primary, Odintsov, Igor, primary, Hartono, Alifiani B., primary, LaQuaglia, Michael P., primary, Slotkin, Emily, primary, Pratilas, Christine A., primary, Lee, Sean Bong, primary, Spraggon, Lee, primary, and Ladanyi, Marc, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure S3 from The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions

Author

Odintsov, Igor, primary, Lui, Allan J.W., primary, Sisso, Whitney J., primary, Gladstone, Eric, primary, Liu, Zebing, primary, Delasos, Lukas, primary, Kurth, Renate I., primary, Sisso, Exequiel M., primary, Vojnic, Morana, primary, Khodos, Inna, primary, Mattar, Marissa S., primary, de Stanchina, Elisa, primary, Leland, Shawn M., primary, Ladanyi, Marc, primary, and Somwar, Romel, primary

Published
2023
Full Text
View/download PDF

44. Figure S4 from Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer

Author

Suzawa, Ken, primary, Offin, Michael, primary, Lu, Daniel, primary, Kurzatkowski, Christopher, primary, Vojnic, Morana, primary, Smith, Roger S., primary, Sabari, Joshua K., primary, Tai, Huichun, primary, Mattar, Marissa, primary, Khodos, Inna, primary, de Stanchina, Elisa, primary, Rudin, Charles M., primary, Kris, Mark G., primary, Arcila, Maria E., primary, Lockwood, William W., primary, Drilon, Alexander, primary, Ladanyi, Marc, primary, and Somwar, Romel, primary

Published
2023
Full Text
View/download PDF

46. Figure S2 from Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Author

Rosen, Ezra Y., primary, Johnson, Melissa L., primary, Clifford, Sarah E., primary, Somwar, Romel, primary, Kherani, Jennifer F., primary, Son, Jieun, primary, Bertram, Arrien A., primary, Davare, Monika A., primary, Gladstone, Eric, primary, Ivanova, Elena V., primary, Henry, Dahlia N., primary, Kelley, Elaine M., primary, Lin, Mika, primary, Milan, Marina S.D., primary, Nair, Binoj C., primary, Olek, Elizabeth A., primary, Scanlon, Jenna E., primary, Vojnic, Morana, primary, Ebata, Kevin, primary, Hechtman, Jaclyn F., primary, Li, Bob T., primary, Sholl, Lynette M., primary, Taylor, Barry S., primary, Ladanyi, Marc, primary, Jänne, Pasi A., primary, Rothenberg, S. Michael, primary, Drilon, Alexander, primary, and Oxnard, Geoffrey R., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure S1 from A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

Author

Drilon, Alexander, primary, Somwar, Romel, primary, Wagner, Jacob P., primary, Vellore, Nadeem A., primary, Eide, Christopher A., primary, Zabriskie, Matthew S., primary, Arcila, Maria E., primary, Hechtman, Jaclyn F., primary, Wang, Lu, primary, Smith, Roger S., primary, Kris, Mark G., primary, Riely, Gregory J., primary, Druker, Brian J., primary, O'Hare, Thomas, primary, Ladanyi, Marc, primary, and Davare, Monika A., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure 1 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors

Author

Shukla, Neerav, primary, Somwar, Romel, primary, Smith, Roger S., primary, Ambati, Sri, primary, Munoz, Stanley, primary, Merchant, Melinda, primary, D'Arcy, Padraig, primary, Wang, Xin, primary, Kobos, Rachel, primary, Antczak, Christophe, primary, Bhinder, Bhavneet, primary, Shum, David, primary, Radu, Constantin, primary, Yang, Guangbin, primary, Taylor, Barry S., primary, Ng, Charlotte K.Y., primary, Weigelt, Britta, primary, Khodos, Inna, primary, de Stanchina, Elisa, primary, Reis-Filho, Jorge S., primary, Ouerfelli, Ouathek, primary, Linder, Stig, primary, Djaballah, Hakim, primary, and Ladanyi, Marc, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 3 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors

Author

Shukla, Neerav, primary, Somwar, Romel, primary, Smith, Roger S., primary, Ambati, Sri, primary, Munoz, Stanley, primary, Merchant, Melinda, primary, D'Arcy, Padraig, primary, Wang, Xin, primary, Kobos, Rachel, primary, Antczak, Christophe, primary, Bhinder, Bhavneet, primary, Shum, David, primary, Radu, Constantin, primary, Yang, Guangbin, primary, Taylor, Barry S., primary, Ng, Charlotte K.Y., primary, Weigelt, Britta, primary, Khodos, Inna, primary, de Stanchina, Elisa, primary, Reis-Filho, Jorge S., primary, Ouerfelli, Ouathek, primary, Linder, Stig, primary, Djaballah, Hakim, primary, and Ladanyi, Marc, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Materials and Methods from The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions

Author

Odintsov, Igor, primary, Lui, Allan J.W., primary, Sisso, Whitney J., primary, Gladstone, Eric, primary, Liu, Zebing, primary, Delasos, Lukas, primary, Kurth, Renate I., primary, Sisso, Exequiel M., primary, Vojnic, Morana, primary, Khodos, Inna, primary, Mattar, Marissa S., primary, de Stanchina, Elisa, primary, Leland, Shawn M., primary, Ladanyi, Marc, primary, and Somwar, Romel, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results